|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Medullary thyroid carcinoma in a child with a new RET mutation and a RET polymorphism.
|
15844786 |
2005 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Medullary thyroid carcinoma (MTC) is responsible for 13.4% of the total deaths attributable to thyroid cancer in human beings and research on MTC over the last 40 years has identified the RET proto-oncogene as a very relevant component of development of both sporadic and hereditary MTC.
|
18502338 |
2008 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We designed the present study to evaluate in a single laboratory, using the same methodologies, the pattern of RET/PTC activation in thyroid tumors from different groups of patients (exposed or not exposed to radiation, children or adults, with benign or malignant tumors) in relationship to the above mentioned variables.
|
11443191 |
2001 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma.
|
18226854 |
2008 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These targets include the proto-oncogenes BRAF and RET, known to be common mutations in thyroid cancer; vascular endothelial growth factor receptor and platelet-derived growth factor receptor, associated with angiogenesis; and the sodium-iodide symporter, with the aim of restoring its expression and hence radioactive iodine uptake.
|
20142332 |
2010 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
|
18756447 |
2009 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset.
|
14557473 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.
|
15741265 |
2005 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Three novel mutations in the RET proto-oncogene.
|
11692159 |
2001 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions.
|
12161537 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.
|
16419493 |
2005 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings in a cellular context relevant to the pathological function of RET oncogenes support the role of Ret oncoproteins as useful targets for therapeutic intervention, and suggest RPI-1 as a promising candidate for preclinical development in the treatment of thyroid tumors expressing RET oncogenes.
|
12943231 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.
|
15523405 |
2004 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
|
9861322 |
1998 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation.
|
12193298 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants.
|
26652860 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
CCDC6 was originally identified in chimeric genes as caused by chromosomal translocation involving the RET protooncogene in some thyroid tumors.
|
23145146 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer is frequently associated with the oncogenic conversion of the RET receptor tyrosine kinase.
|
16778204 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.
|
17185892 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.
|
16483615 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
|
17464312 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Targeting RET for thyroid cancer therapy.
|
19028457 |
2009 |